While most of the reversion mutations in our cohort are in tumor histologies that have traditionally been thought to be driven by BRCA1/2, in this study we highlight the development of reversion mutations in select non-canonical histologies and verify the presence of an HRD phenotype with molecular signatures within whole-exome sequencing (WES). This evidence concerns the gene BRCA1 and neoplasm.